Adalimumab for Psoriatic Arthritis
The FDA has approved adalimumab (Humira®, Abbott) for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis (PsA). PsA is a chronic autoimmune disease that combines the symptoms of arthritis (joint pain and inflammation) with those of psoriatic skin disease (dry, scaly skin). It is the first new disease indication for this [...]
Read User's Comments